Current NCCN guidelines recommend CRC surveillance in LS every one to two years beginning between ages 20 and 25 for high-risk variants (MLH1, MSH2, and EPCAM) and every one to three years beginning between ages 30 and 35 for MSH6 and PMS2 carriers [7]. The gene discussed is MSH2; the disease is colorectal carcinoma.